Repatha — Total revenues
Products & Services · Total revenuesAmgen Repatha — Total revenues remained flat by 0.0% to $754.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 35.7%, from $555.50M to $754.00M. Over 2 years (FY 2023 to FY 2025), Repatha — Total revenues shows an upward trend with a 35.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, expanded insurance coverage, or increased physician adoption, while a decrease may signal heightened competition from biosimilars or alternative therapies.
Detailed definition
This metric represents the total gross revenue generated from the global sales of a specific biologic therapeutic produc...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic product lines at other large-cap pharmaceutical and biotechnology companies.
amgn_segment_repatha_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.64B | $2.22B | $3.02B |
| YoY Change | — | +35.9% | +35.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's repatha — total revenues?
- Amgen (AMGN) reported repatha — total revenues of $754.00M in Q4 2025.
- How has Amgen's repatha — total revenues changed year-over-year?
- Amgen's repatha — total revenues increased by 35.7% year-over-year, from $555.50M to $754.00M.
- What is the long-term trend for Amgen's repatha — total revenues?
- Over 2 years (2023 to 2025), Amgen's repatha — total revenues has grown at a 35.8% compound annual growth rate (CAGR), from $1.64B to $3.02B.
- What does repatha — total revenues mean?
- The total sales revenue generated by the company's specific cholesterol-lowering drug product line.